Investor Relations

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

Recent Releases

Date Title and Summary
Toggle Summary Celldex Provides Corporate Update and Reports First Quarter 2019 Results
HAMPTON, N.J. , May 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019 . “Celldex presented positive data across multiple programs at AACR in April, including from our promising CDX-1140
Toggle Summary Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
--CDX-1140 has achieved good systemic exposure without reaching a maximum tolerated dose to date-- --Addition of dendritic cell growth factor CDX-301 enhances cytokine response without additive toxicity at dose levels tested to date-- --Tumor specific expansion cohorts planned-- HAMPTON, N.J.

Upcoming Events

There are currently no events to display.

Featured Financial Reports

Show all

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline